Onesource Specialty Pharma Limited vs Zydus Lifesciences Limited

A side-by-side comparison of Onesource Specialty Pharma Limited (ONESOURCE) and Zydus Lifesciences Limited (ZYDUSLIFE) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, Zydus Lifesciences Limited leads ONESOURCE vs ZYDUSLIFE on 9 of 14 metrics (1 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation22
  • Profitability04
  • Growth10
  • Size & financial health13
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

Even

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

-364.50
P/E ratio
22.42
3.04
P/B ratio
4.11
0.00%
Dividend yield
0.09%
₹-6.44
EPS
₹50.09

Profitability

ZYDUSLIFE takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

-1.27%
Return on equity
18.59%
0.43%
Return on capital
18.07%
21.40%
EBITDA margin
31.22%
-5.19%
Net margin
18.87%

Growth

ONESOURCE takes 1/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

231.57%
Revenue CAGR (3Y)
16.35%
—
Profit CAGR (3Y) even
34.80%

Size & financial health

ZYDUSLIFE takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹16,154 Cr
Market cap
₹1.12L Cr
₹1,422 Cr
Revenue
₹27,148 Cr
₹-74 Cr
Net profit
₹5,124 Cr
0.22
Debt / equity
0.46
Onesource Specialty Pharma Limited
  • + ["Company has delivered good sales growth of 132.3% CAGR over last 5 years"]
  • − ["Company has a low return on equity of -22.7% over last 3 years.", "Company reported a net loss of ₹74 Cr in its latest financial year."]
Zydus Lifesciences Limited
  • + ["Company has delivered good profit growth of 18.6% CAGR over last 5 years", "Company has a good return on equity (ROE) track record: 3 Years ROE 20.9%"]
  • − []
Onesource Specialty Pharma Limited full analysis Zydus Lifesciences Limited full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.